Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
As of close of business last night, Ocular Therapeutix Inc’s stock clocked out at $12.2, up 2.22% from its previous closing price of $11.94. In other words, the price has increased by $2.22 from its previous closing price. On the day, 2.97 million shares were traded. OCUL stock price reached its highest trading level at $12.33 during the session, while it also had its lowest trading level at $11.84.
Ratios:
To gain a deeper understanding of OCUL’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.02 and its Current Ratio is at 10.09. In the meantime, Its Debt-to-Equity ratio is 0.25 whereas as Long-Term Debt/Eq ratio is at 0.24.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Chardan Capital Markets on September 15, 2025, initiated with a Buy rating and assigned the stock a target price of $21.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 08 ’25 when Anderman Todd sold 11,132 shares for $12.34 per share. The transaction valued at 137,369 led to the insider holds 87,568 shares of the business.
TODD ANDERMAN bought 11,132 shares of OCUL for $137,400 on Oct 08 ’25. On Oct 02 ’25, another insider, Kaiser Peter, who serves as the Chief Development Officer of the company, sold 9,653 shares for $11.03 each. As a result, the insider received 106,473 and left with 194,440 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, OCUL now has a Market Capitalization of 2585231616 and an Enterprise Value of 1808546688. For the stock, the TTM Price-to-Sale (P/S) ratio is 45.63 while its Price-to-Book (P/B) ratio in mrq is 6.90. Its current Enterprise Value per Revenue stands at 31.917 whereas that against EBITDA is -7.621.
Stock Price History:
The Beta on a monthly basis for OCUL is 1.53, which has changed by 0.07678723 over the last 52 weeks, in comparison to a change of 0.13033986 over the same period for the S&P500. Over the past 52 weeks, OCUL has reached a high of $13.85, while it has fallen to a 52-week low of $5.78. The 50-Day Moving Average of the stock is -0.36%, while the 200-Day Moving Average is calculated to be 30.66%.
Shares Statistics:
It appears that OCUL traded 2.66M shares on average per day over the past three months and 4009150 shares per day over the past ten days. A total of 211.90M shares are outstanding, with a floating share count of 177.56M. Insiders hold about 16.21% of the company’s shares, while institutions hold 65.02% stake in the company. Shares short for OCUL as of 1759190400 were 13557599 with a Short Ratio of 5.10, compared to 1756425600 on 13835161. Therefore, it implies a Short% of Shares Outstanding of 13557599 and a Short% of Float of 7.8200005.
Earnings Estimates
. The current rating of Ocular Therapeutix Inc (OCUL) reflects the combined expertise of 3.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$0.36, with high estimates of -$0.31 and low estimates of -$0.4.
Analysts are recommending an EPS of between -$1.33 and -$1.56 for the fiscal current year, implying an average EPS of -$1.43. EPS for the following year is -$1.41, with 3.0 analysts recommending between -$1.3 and -$1.57.
Revenue Estimates
In. The current quarter, 12 analysts expect revenue to total $14.57M. It ranges from a high estimate of $19M to a low estimate of $12.56M. As of. The current estimate, Ocular Therapeutix Inc’s year-ago sales were $15.43MFor the next quarter, 12 analysts are estimating revenue of $16.19M. There is a high estimate of $24.6M for the next quarter, whereas the lowest estimate is $13.5M.
A total of 12 analysts have provided revenue estimates for OCUL’s current fiscal year. The highest revenue estimate was $67.8M, while the lowest revenue estimate was $50.3M, resulting in an average revenue estimate of $54.92M. In the same quarter a year ago, actual revenue was $63.72MBased on 12 analysts’ estimates, the company’s revenue will be $65.2M in the next fiscal year. The high estimate is $82.9M and the low estimate is $52.3M.
